CORRECTION

Correction: Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study Geraldine Dominiak-Felden, Corrado Gobbo, François Simondon

The image for Fig 1 is incorrect. Please see the correct Fig 1 here.

OPEN ACCESS Citation: Dominiak-Felden G, Gobbo C, Simondon F (2016) Correction: Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study. PLoS ONE 11(1): e0148665. doi:10.1371/journal.pone.0148665 Published: January 29, 2016 Copyright: © 2016 Dominiak-Felden et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PLOS ONE | DOI:10.1371/journal.pone.0148665 January 29, 2016

1/3

Fig 1. Incidence of genital warts per 100 000 individuals (dashed line: females; solid line: males) and qHPV vaccine uptake in individuals aged 16– 22 years (A), 23–30 years (B), 31–40 years (C) and 41–59 years (D) affiliated to the MLOZ sick fund (Belgium) between 2006 and 2013 (standardised estimates). doi:10.1371/journal.pone.0148665.g001

There are errors in the fourth row of Table 2. Please see the corrected Table 2 here.

Table 2. Characteristics of the vaccine effectiveness study population as a function of their vaccination status. Vaccination status

n

Age* at 1st dose (years)

Age* end of study (years)

Number with GWs (%)

Age* 1st GWs episode (years)

Unvaccinated

63 180

-

20.2

244 (0.39)

20.1

1 dose

4 020

15.8

20.1

16 (0.21)

19.1

2 doses

3 587

3 doses

35 792

14.7

19.7

14 (0.04)

19.1

3 doses (as per schedule)

24 791

14.7

19.9

12 (0.05)

19.3

*Median age doi:10.1371/journal.pone.0148665.t001

PLOS ONE | DOI:10.1371/journal.pone.0148665 January 29, 2016

2/3

There is an error in the third sentence of the last paragraph of the Results section. The correct sentence is: In this second sensitivity analysis, the GWs IR was 113.9 (95%CI: 101.3–128.1) per 100,000 person-years in the non-qHPV vaccine group vs 14.2 (95% CI: 8.8; 22.8) per 100,000 person-years among women fully vaccinated with qHPV vaccine.

Reference 1.

Dominiak-Felden G, Gobbo C, Simondon F (2015) Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study. PLoS ONE 10(7): e0132404. doi:10.1371/ journal.pone.0132404 PMID: 26147096

PLOS ONE | DOI:10.1371/journal.pone.0148665 January 29, 2016

3/3